Table 4.

Assessment of the prognostic role of onset of first progression and subsequent treatment initiation (coded as time-dependent covariates) on overall survival after each line of treatment

Event of interestLine of treatmentNumber at riskNumber of deathsMedian time (IQR) to event, mo*Without adjustmentAdjusted for sIPSSWM†
HR (95% CI)PHarrell C (95% CI)HR (95% CI)PHarrell C (95% CI)
Onset of subsequent progression After first 115 69 63 (37-101) 2.94 (1.22-7.81) .02 0.53 (0.48-0.59) 2.98 (1.19-8.27) .013 0.73 (0.65-0.81) 
 After second* 64 42 53 (26-85) 1.34 (0.56-3.13) .49     
 After third* 38 23 51 (32-71) 2.19 (0.73-6.55) .12     
Onset of subsequent treatment initiation After first 115 69 69 (41-106) 2.56 (1.38-4.89) .006 0.57 (0.51-0.62) 2.60 (1.35-5.16) .009 0.72 (0.63-0.81) 
 After second* 64 42 56 (28-93) 1.41 (0.66-3.04) .37     
 After third* 38 23 59 (43-79) 1.63 (0.51-5.23) .4     
Event of interestLine of treatmentNumber at riskNumber of deathsMedian time (IQR) to event, mo*Without adjustmentAdjusted for sIPSSWM†
HR (95% CI)PHarrell C (95% CI)HR (95% CI)PHarrell C (95% CI)
Onset of subsequent progression After first 115 69 63 (37-101) 2.94 (1.22-7.81) .02 0.53 (0.48-0.59) 2.98 (1.19-8.27) .013 0.73 (0.65-0.81) 
 After second* 64 42 53 (26-85) 1.34 (0.56-3.13) .49     
 After third* 38 23 51 (32-71) 2.19 (0.73-6.55) .12     
Onset of subsequent treatment initiation After first 115 69 69 (41-106) 2.56 (1.38-4.89) .006 0.57 (0.51-0.62) 2.60 (1.35-5.16) .009 0.72 (0.63-0.81) 
 After second* 64 42 56 (28-93) 1.41 (0.66-3.04) .37     
 After third* 38 23 59 (43-79) 1.63 (0.51-5.23) .4     
*

Complete clinical monitoring was missing in some patients after the second and the third lines of treatment.

†

Cox regression model including sIPSSWM at initiation of first-line treatment (available in 104 patients) and sIPSSWM by time interaction.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal